Rising Prostate Cancer Survival in the UK: Implications for Actuarial Tables

A major national study in the UK has identified a significant improvement in survival rates for men diagnosed with metastatic prostate cancer. The study, published in BJU International, analyzed data from 45,339 patients between 2015 and 2022. Findings indicate that the proportion of men surviving three years post-diagnosis increased from 44% in 2015 to 53% in 2022.

Actuarial Implications

From an actuarial perspective, these results serve as a critical signal for risk modeling in life and critical illness insurance. Although metastatic prostate cancer has traditionally been considered incurable, the efficacy of new hormonal therapies and chemotherapy has reduced mortality. Researchers estimated the relative risk of prostate cancer death for the 2022 cohort to be 24% lower than in previous periods.

For insurers and actuaries, these data necessitate a review of mortality tables and morbidity forecasts. Where previous actuarial models classified this diagnosis as highly lethal, current trends require adjustments to long-term annuity and life insurance reserves. In terms of operational risk, advancements in diagnostic and treatment methods directly alter 'longevity risk' parameters.

Study authors note that despite a plateau in progress during the COVID-19 pandemic, the overall trend remains positive. For actuaries, the primary task is the mathematical assessment of how this medical progress impacts insurance claims. This material is for informational purposes only and underscores the importance of updating data in actuarial calculations.

Actuarial Conclusion: A 24% reduction in the risk of death from metastatic cancer alters the balance between 'mortality risk' and 'longevity risk' in life insurance portfolios. Actuaries are advised to conduct stress testing of reserves incorporating these updated medical findings.

Source: Knowridge Science Report, 2026-10-07.